BTK
BTK (Bruton's tyrosine kinase) inhibitors are compounds that specifically target and inhibit BTK, a crucial enzyme involved in B-cell receptor signaling and the regulation of angiogenesis. BTK plays a significant role in the proliferation and survival of cancer cells, particularly in hematological malignancies. By inhibiting BTK, these compounds can disrupt angiogenesis and tumor growth, making them valuable in cancer therapy. At CymitQuimica, we offer a range of high-quality BTK inhibitors to support your research in oncology, immunology, and angiogenesis.
Found 166 products of "BTK"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
ARQ 531
CAS:ARQ-531: potent oral BTK inhibitor, anti-cancer potential, IC50 of 0.85/0.39 nM for WT/C481S-BTK.Formula:C25H23ClN4O4Purity:98.68% - 99.63%Color and Shape:SolidMolecular weight:478.93AS-1763
CAS:AS-1763 is an orally available and selective BTK inhibitor with an IC50 of 0.85 nM.Formula:C33H31FN6O3Purity:≥95%Color and Shape:SolidMolecular weight:578.64Orelabrutinib
CAS:Orelabrutinib (ICP-022) is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).Formula:C26H25N3O3Purity:97.77% - 99.54%Color and Shape:SolidMolecular weight:427.49Ref: TM-T12317
1mg86.00€5mg177.00€10mg299.00€25mg492.00€50mg682.00€100mg897.00€500mg1,791.00€1mL*10mM (DMSO)205.00€Tirabrutinib hydrochloride
CAS:Tirabrutinib hydrochloride is a potent, highly selective, irreversible oral BTK inhibitor.Cost-effective and quality-assured.Formula:C25H23ClN6O3Purity:99.27% - 99.95%Color and Shape:SolidMolecular weight:490.94Rilzabrutinib
CAS:Rilzabrutinib (PRN1008) is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).Formula:C36H40FN9O3Purity:98.28% - 99.76%Color and Shape:SolidMolecular weight:665.76Ref: TM-T12542
1mg94.00€5mg222.00€10mg356.00€25mg620.00€50mg893.00€100mg1,251.00€500mg2,502.00€1mL*10mM (DMSO)325.00€MT-802
CAS:MT-802 is an effective BTK degrader based on PROTAC technology (DC50: 1 nM). MT-802 has the potential to treat C481S mutant chronic lymphocytic leukemia (CLL).Formula:C41H41N9O8Purity:95.93% - 97%Color and Shape:SolidMolecular weight:787.82Ref: TM-T16157
1mg92.00€5mg177.00€10mg269.00€25mg510.00€50mg692.00€100mg888.00€200mg1,251.00€1mL*10mM (DMSO)231.00€Btk inhibitor 2
CAS:Btk inhibitor 2 (BGB-3111 analog) is a BTK inhibitor.Formula:C24H25N5O3Purity:99.94%Color and Shape:SolidMolecular weight:431.49Ref: TM-T10629
1mg34.00€2mg49.00€5mg74.00€10mg98.00€25mg215.00€50mg356.00€100mg434.00€1mL*10mM (DMSO)82.00€IBT6A
CAS:IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.Formula:C22H22N6OPurity:99.8% - 99.88%Color and Shape:SolidMolecular weight:386.45SJF620 hydrochloride
CAS:SJF620 hydrochloride is a PROTAC that utilizes a lenalidomide analog to recruit CRBN and ligands to target Btk, exhibiting a DC50 of 7.9 nM [1].Formula:C41H45ClN8O7Purity:98%Color and Shape:SolidMolecular weight:797.3FDA-Approved Kinase Inhibitor Library
A unique collection of 263 kinase inhibitors/regulators for specific targeting of kinases, ready for high-throughput screening and high-content screening.
Color and Shape:LiquidDD 03-171
CAS:Potent BTK Degrader, IC50=5.1nM, CRBN-dependent, suppresses MCL; degrades Ibrutinib-resistant BTK, no kinases binding, reduces tumors in models.Formula:C55H62N10O8Color and Shape:SolidMolecular weight:991.163BTK-IN-5
CAS:BTK-IN-5 is a covalent inhibitor of Bruton's tyrosine kinase (BTK) designed for the treatment of medical conditions including cardiovascular diseases,Formula:C23H32N4O5Color and Shape:SolidMolecular weight:444.532GBD-9
CAS:GBD-9, a dual-mechanism degrader, effectively promotes the degradation of BTK and GSPT1 through recruitment of E3 ligase cereblon (CRBN).Formula:C44H47N9O6Purity:98%Color and Shape:SolidMolecular weight:797.9TLT8
TLT8 is a ByeTAC protein degrader that targets BTK. It induces BTK degradation by non-covalently binding to Rpn-13 and BTK. TLT8 is applicable in research on chronic lymphocytic leukemia.Color and Shape:Odour SolidNRX-0492
CAS:NRX-0492: orally active BTK degrader, induces ubiquitylation/proteasomal breakdown, potent with DC50 ≤0.2 nM, DC90 ≤0.5 nM, disrupts BCR signaling.Formula:C43H51N11O6Color and Shape:SolidMolecular weight:817.94PTD10
CAS:PTD10, a highly potent PROTAC BTK degrader, exhibits a DC50 of 0.5 nM and a KD of 2.28 nM.Formula:C49H51N11O8Purity:99.12%Color and Shape:SolidMolecular weight:922PROTAC BTK Degrader-1
CAS:Potent, selective oral PROTAC BTK Degrader-1; IC50: 34.51 nM (WT), 64.56 nM (BTK-481S); reduces BTK protein, inhibits tumors.
Formula:C43H43N9O4Color and Shape:SolidMolecular weight:749.86BTK ligand-14
BTKligand-14 is a PROTAC-targeting ligand for BTK, suitable for the synthesis of FDU73.Color and Shape:Odour SolidBRK inhibitor P21d hydrochloride
CAS:BRK inhibitor P21d HCl targets breast tumor kinase with 30 nM IC50, suppresses p-SAM68 at 52 nM, useful for in vivo breast cancer research.Formula:C23H23ClFN7O2Color and Shape:SolidMolecular weight:483.93Tyrosinase-IN-16
CAS:Tyrosinase-IN-16 inhibited tyrosinase.Formula:C8H6BrN3SPurity:99.94%Color and Shape:SolidMolecular weight:256.12
